BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:18 PM
 | 
Jun 03, 2010
 |  BC Extra  |  Clinical News

Abbott releases ASCO abstracts

Abbott Laboratories (NYSE:ABT) announced the availability of abstracts slated for presentation at the American Society of Clinical Oncology meeting in Chicago, including data from three Phase II trials of linifanib. In advanced renal cell carcinoma (RCC), daily oral linifanib led to an overall response rate (ORR) of 9.4%, with median progression-free survival...

Read the full 244 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >